Skip to main content

ACR 2026 RheumNow ILD Topic Compilation a

Nov 16, 2026 12:56 pm
New Treatments in ILD Mortality and Myositis in ILD Screen-detected ILD in Scleroderma Can we do Pulmonary Testing at Home VALORous Efforts in Dermatomyositis Interstitial Lung Disease

Transcription

This is an ACR 2026 podcast coming to you from ACR in Orlando. Hope you enjoy it.

This Room Now podcast is brought to you with support from Boehringer Ingelheim. Boehringer Ingelheim is committed to advancing research in rheumatology through ongoing work in progressive pulmonary fibrosis, interstitial lung disease, and systemic autoimmune rheumatic diseases, including systemic sclerosis, myositis, and beyond. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies in areas of high unmet medical need. Boehringer Ingelheim is proud to support RheumNow and the rheumatology community. Thank you for listening.

Hi, everyone. I'm Doctor. Elizabeth Volkmann, an adult rheumatologist from UCLA, and I'm reporting to you live from the ACR in Orlando 2026. Yesterday, I had the opportunity to moderate a session on new treatments for autoimmune interstitial lung disease, and we got to hear the perspective of a pulmonologist as well as a rheumatologist. The new treatments that we're talking about are anti fibrotic and specifically Narendolamast or Jascade.

This is a medication that was recently approved for progressive pulmonary fibrosis. Now in the study that looked at this medication, they looked at patients who had all different causes of progressive pulmonary fibrosis. In this study, three twenty five patients had autoimmune interstitial lung disease and treatment with narendolamaz resulted in a slower decline in forced vital capacity compared with placebo. So during this lecture, we had these two esteemed doctors go through patient cases and described where they see narendola mass fitting in the paradigm of treating people with autoimmune lung disease. Now it's important to keep in mind that we know our patients with autoimmune disease have involvement outside of the lung.

So if you're thinking about treating a patient with autoimmune lung disease, you have to think about the joints, the muscles, the skin, all of the systems that can be involved. Immunomodulatory therapies like mycophenolate, rituximab, tocilizumab are still a mainstay for how we treat autoimmune interstitial lung disease. But treatments like Nirandolamask could be added on to improve outcomes for people who live with ILD. I'm sure we're going to see a lot more in the future on this medication, and I'm really thrilled to be able to share this information with you today.

Hi. I'm Derek Mueller, PA from Detroit, Michigan, and I'm recording here from ACR Convergence twenty twenty six in Orlando, Florida. And today, I'm here to talk to you about something that we all get a little freaked out about, and that's myositis and the mortality risk. So, I'm here to talk to you about abstract number zero six four five, and this was looking at newly diagnosed myositis patients who have associated interstitial lung disease. This is a cohort of forty one newly diagnosed myositis associated ILD patients, specifically looking at the two year mortality as well as lung transplant risk of these patients over time.

This population included a median age of 57 year old patients, majority female. And this was also a pretty sick population. Forty four percent of these patients were on supplemental oxygen at time of enrollment into this... Into the study, and forty... Fourteen percent of patients were hospitalized at the beginning of this study period as well.

So over the two year period of observation, fifteen percent of these patients unfortunately died, and the average time of which these patients, passed was at eight and a half months. Ten percent of these patients were transplanted lung transplant and this occurred around thirteen months. Of the of the survivors in this group, only thirteen percent of patients did progress and and and forty seven percent actually did see an improvement and that was by an equal or greater to 10% improvement in predicted predicted FVC. And these improvements in this... In these patients who are the survivors, they they they actually improved regardless of if they're on supplemental oxygen at baseline.

So I think some key takeaways here is is that interstitial lung disease and myositis is front loaded. The severity seems to be the most at the at the beginning of the course, and this is something where with proper and aggressive treatment, these are patients who can survive and thrive, and they can improve over time.

Hello. This is Eric Dine live here with RheumNow at ACR Convergence. I'm gonna talk about, screening for ILD in patients with systemic sclerosis scleroderma. I'm gonna talk about abstract two forty four, which looked at prospective study from two New York based scleroderma centers. They looked at one hundred and six patients, all with relatively recent diagnoses within the last five years of first Raynaud's symptom onset.

Screening with the battery of testing, forced scleroderma including the high resolution CT scan, pulmonary function tests, pulmonary examination with auscultation of the lungs, serum testing including CRP, IL-six, surfactant protein D, and matrix metalloproteinase seven, MMP-seven. And they looked at the patients with clinical ILD, screening detected ILD versus no ILD. The screening detecting not having any findings on examination, no crackles, no rales, and and no clinical symptoms. And they compared them both at baseline and then at twelve months. Study participants, fifty three patients were looked at prospectively, seventy nine percent were female, fifty eight percent of them had diffuse disease, and they found twenty four percent had clinically defined ILD, nineteen percent with the screening detected ILD, and fifty eight percent without ILD.

Patients, sixty one percent, or of the sixty one patients who did not have any crackles on exam, one third of them was found to have ILD on high resolution CT scan and on follow-up of them. Thirty three percent without any symptoms may still have ILD. Of the patients with screen detected ILD, they had a higher MMP7 in the blood work as compared to the no ILD patients. They did report at twelve months some symptoms of dyspnea, but no change in FVC or DLCO as compared to the no ILD patients. So this is a study that demonstrates to me that of the new onset ILD patients, up to a third of the patients without any pulmonary findings can have ILD on screening, we should have our suspicion high for that and be following them.

For more coverage of RheumNow, at ACR Convergence, tune into RheumNow. Hello, this is Eric Dine here at ACR Convergence with RheumNow. I'm here with Doctor. Liu from Johns Hopkins. Tell me about your study about pulmonary function testing at home.

All right. So our study is about assessing the added values of host barometry on top of the hospital PFTs that we're doing every four to twelve months. And because there is this gap in between, there were potentially missing windows of opportunity to intervene. So we wanted to see if at home testing can fill that gap. Mhmm.

So, in our study, we have three sub questions. The first one is whether patients complete these studies Mhmm. Complete these readings. And then the second question is whether the home spirometry is correlated and in high agreements with the hospital PFT. And then the last question is whether we can do longitudinal trajectory modeling that's better with the denser amount of data for home spirometries compared to the sparse data for hospital PFT.

And these are just the the little, spirometers that you can do at home?

Yes. So these are handheld device that they take home and then they will perform the testing and there's an inbuilt quality control systems that you have to pass the test and then, that will get uploaded to an app or a platform and then we can collect those data.

So tell me what you found.

Yeah, so we found that, so in our studies we have 28 patients who stay within the studies. There were originally 36 recorded patients and then twenty one of them completed at least six months of data, so patients didn't complete these Hall's barometer readings, so that's very encouraging. And then the second thing that we found is that they're in high agreement, very correlated with a coefficient of 0.99 with the hospital PFT that's matched within plus or minus three days for each of the patients. So, they're very reliable as compared to a hospital pulmonary function test. And then finally, we found that it can support much better and more updated slow estimates to understand where patients are currently and also if they're declining fast and at a faster or slower

So you check it a little bit more serially when it's at home?

Yes, and it gives us a much more granular image and it gives us confidence if the patient is being stable or if they're improving or declining.

And this was a study specifically for scleroderma patients with established ILD?

Yes.

But it could be presumably used for any interstitial lung disease Correct.

It can be extended, if we have a large cohort.

Yeah. Thank you very much for telling us about your trial. For more coverage of ACR convergence, tune in to RheumNow.

Thank you so much.

Thank you. Thank you for having me. Yeah.

Hi. I'm Derek Mueller, PA from Detroit, Michigan, and I'm here at ACR twenty twenty six in Orlando, Florida. And what I'd like to talk to you about today is valorous efforts in dermatomyositis interstitial lung disease. So we know that interstitial lung disease is a major comorbidity in inflammatory myopathies. Dermatomyositis is no exception.

And I wanna talk about abstract number one five eight six, which is a sub analysis of the VALOR trial, which was the pivotal study that got brepocitinib approved for the treatment in patients with dermatomyositis. Now patients with interstitial lung disease were not excluded from this trial, and the sub analysis looked at the twenty percent of patients with ILD, in in this trial who were enrolled and and specifically aimed to look at outcomes, of dermatomyositis patients with and without ILD in that sub analysis. The efficacy endpoints looking at total improvement score in the patients with and without interstitial lung disease were actually quite comparable. So it didn't seem like that was necessarily a factor in efficacy of, muscle domain endpoints. There was also very similar steroid sparing efficacy looking at ILD patients without...

With and without ILD... Patients with and without ILD. Now there's definitely some big time caveats here given that this is a sub analysis and it's a relatively small population of ILD patients nestled within the, within the VALOR trial. VALOR was never powered to rigorously assess and evaluate DM ILD patients. Also, the the ILD in these patients was relatively mild.

The median FVC was seventy seven point five percent. And just for a frame of reference, normal FVC, is is greater than 80%, so relatively mild. So key takeaways here that there was demonstrated efficacy in these muscle domain specific endpoints in DM patients with and without ILD. And it didn't seem like steroid use or the steroid sparing was an issue even in these patients with ILD. They demonstrated, similar outcomes with steroid sparing, so the ILD was not necessarily driving the the prescription and escalation of steroids here.

And then some other caveats just to wait... Take away too that in this population, in the VALOR trial, patients were not excluded if they were on a background conventional, agent. So patients in the setting of ILD or just DM in general, they could still continue, their their mycophenolate, and such if they were if they were on that, on a stable dose at enrollment. So just think about that when when you consider this trial as well. So what this means to me is that we should consider brefacitinib in DM patients with or without ILD, but I think this is a call to action to better understand the therapies that we have our our our disposal and the impact that they may have on patients with dermatomyositis related interstitial lung disease.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×